Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib in HRD-positive Castration-Resistant Prostate Cancer
NCT04951492Phase 2Terminated
- Sponsor
- University of Washington
- Start
- Nov 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib in prostate adenocarcinoma, sponsored by University of Washington. Started Nov 2022; status: terminated.
02
Drugs
olaparib
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on NCT04951492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04951492.